Jazz Ebitda vs Cost Of Revenue Analysis

JAZZ Stock

USD 125.10 5.86 4.91%

Jazz Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jazz Pharmaceuticals PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jazz Pharmaceuticals PLC is a good investment. Please check the relationship between Jazz Pharmaceuticals Ebitda and its Cost Of Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Ebitda vs Cost Of Revenue

Ebitda vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jazz Pharmaceuticals PLC Ebitda account and Cost Of Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Jazz Pharmaceuticals' Ebitda and Cost Of Revenue is 0.67. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Jazz Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Jazz Pharmaceuticals' Ebitda and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Jazz Pharmaceuticals PLC are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Ebitda i.e., Jazz Pharmaceuticals' Ebitda and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.67

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Ebitda

Cost Of Revenue

Cost of Revenue is found on Jazz Pharmaceuticals PLC income statement and represents the costs associated with goods and services Jazz Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Jazz Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jazz Pharmaceuticals PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, Jazz Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.39 in 2024, despite the fact that Tax Provision is likely to grow to (177.5 M).

	2021	2022	2023	2024 (projected)
Gross Profit	2.7B	3.1B	3.4B	3.6B
Total Revenue	3.1B	3.7B	3.8B	4.0B

Gross Profit Total Revenue

Jazz Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Common Stock Shares Outstanding		0.43	0.34	0.39	0.32	0.53	0.36	0.41	0.3	0.4	0.35	0.46	0.42	0.27	0.32	0.35	0.4	0.41	0.49	0.07	0.36	0.22	0.28	0.53	0.36	0.36
Total Assets	0.43		0.98	0.97	0.9	0.91	0.94	0.79	0.96	0.75	0.96	0.71	0.99	0.87	0.65	0.98	0.61	0.98	0.99	0.11	0.98	0.89	0.96	0.98	0.98	0.95
Short Long Term Debt Total	0.34	0.98		0.98	0.91	0.81	0.95	0.7	0.99	0.61	0.97	0.69	0.97	0.85	0.59	1.0	0.51	0.96	0.96	-0.04	0.99	0.94	0.97	0.94	1.0	0.9
Other Current Liab	0.39	0.97	0.98		0.93	0.83	0.9	0.7	0.95	0.64	0.97	0.75	0.95	0.89	0.63	0.97	0.59	0.98	0.96	0.02	0.96	0.89	0.97	0.96	0.98	0.9
Total Current Liabilities	0.32	0.9	0.91	0.93		0.79	0.83	0.54	0.85	0.61	0.92	0.86	0.85	0.88	0.45	0.87	0.71	0.95	0.88	0.09	0.86	0.77	0.9	0.9	0.9	0.87
Total Stockholder Equity	0.53	0.91	0.81	0.83	0.79		0.8	0.86	0.78	0.93	0.81	0.69	0.88	0.8	0.69	0.8	0.76	0.89	0.91	0.44	0.8	0.68	0.82	0.95	0.82	0.95
Other Liab	0.36	0.94	0.95	0.9	0.83	0.8		0.7	0.96	0.65	0.92	0.57	0.97	0.8	0.44	0.95	0.4	0.89	0.94	-0.09	0.96	0.89	0.88	0.89	0.96	0.87
Property Plant And Equipment Net	0.41	0.79	0.7	0.7	0.54	0.86	0.7		0.73	0.86	0.68	0.39	0.79	0.68	0.82	0.72	0.51	0.74	0.78	0.43	0.73	0.66	0.74	0.8	0.71	0.85
Net Debt	0.3	0.96	0.99	0.95	0.85	0.78	0.96	0.73		0.59	0.96	0.57	0.98	0.8	0.59	0.99	0.4	0.92	0.95	-0.08	0.99	0.96	0.95	0.9	0.99	0.87
Retained Earnings	0.4	0.75	0.61	0.64	0.61	0.93	0.65	0.86	0.59		0.61	0.54	0.72	0.71	0.61	0.61	0.72	0.74	0.76	0.6	0.61	0.44	0.63	0.8	0.63	0.87
Accounts Payable	0.35	0.96	0.97	0.97	0.92	0.81	0.92	0.68	0.96	0.61		0.71	0.95	0.9	0.55	0.97	0.52	0.96	0.95	-0.06	0.96	0.92	0.94	0.93	0.98	0.9
Cash	0.46	0.71	0.69	0.75	0.86	0.69	0.57	0.39	0.57	0.54	0.71		0.63	0.75	0.46	0.65	0.87	0.81	0.72	0.17	0.63	0.5	0.68	0.78	0.68	0.7
Non Current Assets Total	0.42	0.99	0.97	0.95	0.85	0.88	0.97	0.79	0.98	0.72	0.95	0.63		0.83	0.61	0.98	0.5	0.95	0.99	0.03	0.98	0.91	0.94	0.96	0.98	0.92
Non Currrent Assets Other	0.27	0.87	0.85	0.89	0.88	0.8	0.8	0.68	0.8	0.71	0.9	0.75	0.83		0.51	0.83	0.65	0.92	0.86	0.15	0.82	0.7	0.81	0.87	0.85	0.91
Other Assets	0.32	0.65	0.59	0.63	0.45	0.69	0.44	0.82	0.59	0.61	0.55	0.46	0.61	0.51		0.61	0.56	0.64	0.62	0.42	0.61	0.6	0.7	0.68	0.59	0.66
Long Term Debt	0.35	0.98	1.0	0.97	0.87	0.8	0.95	0.72	0.99	0.61	0.97	0.65	0.98	0.83	0.61		0.47	0.95	0.96	-0.07	1.0	0.95	0.96	0.93	1.0	0.88
Cash And Short Term Investments	0.4	0.61	0.51	0.59	0.71	0.76	0.4	0.51	0.4	0.72	0.52	0.87	0.5	0.65	0.56	0.47		0.7	0.59	0.64	0.45	0.3	0.58	0.71	0.5	0.71
Net Receivables	0.41	0.98	0.96	0.98	0.95	0.89	0.89	0.74	0.92	0.74	0.96	0.81	0.95	0.92	0.64	0.95	0.7		0.97	0.14	0.94	0.83	0.94	0.98	0.96	0.95
Good Will	0.49	0.99	0.96	0.96	0.88	0.91	0.94	0.78	0.95	0.76	0.95	0.72	0.99	0.86	0.62	0.96	0.59	0.97		0.08	0.97	0.86	0.92	0.98	0.97	0.94
Short Term Investments	0.07	0.11	-0.04	0.02	0.09	0.44	-0.09	0.43	-0.08	0.6	-0.06	0.17	0.03	0.15	0.42	-0.07	0.64	0.14	0.08		-0.08	-0.18	0.11	0.21	-0.05	0.33
Non Current Liabilities Total	0.36	0.98	0.99	0.96	0.86	0.8	0.96	0.73	0.99	0.61	0.96	0.63	0.98	0.82	0.61	1.0	0.45	0.94	0.97	-0.08		0.95	0.95	0.93	1.0	0.88
Inventory	0.22	0.89	0.94	0.89	0.77	0.68	0.89	0.66	0.96	0.44	0.92	0.5	0.91	0.7	0.6	0.95	0.3	0.83	0.86	-0.18	0.95		0.93	0.82	0.94	0.77
Other Current Assets	0.28	0.96	0.97	0.97	0.9	0.82	0.88	0.74	0.95	0.63	0.94	0.68	0.94	0.81	0.7	0.96	0.58	0.94	0.92	0.11	0.95	0.93		0.93	0.96	0.9
Other Stockholder Equity	0.53	0.98	0.94	0.96	0.9	0.95	0.89	0.8	0.9	0.8	0.93	0.78	0.96	0.87	0.68	0.93	0.71	0.98	0.98	0.21	0.93	0.82	0.93		0.94	0.96
Total Liab	0.36	0.98	1.0	0.98	0.9	0.82	0.96	0.71	0.99	0.63	0.98	0.68	0.98	0.85	0.59	1.0	0.5	0.96	0.97	-0.05	1.0	0.94	0.96	0.94		0.9
Property Plant And Equipment Gross	0.36	0.95	0.9	0.9	0.87	0.95	0.87	0.85	0.87	0.87	0.9	0.7	0.92	0.91	0.66	0.88	0.71	0.95	0.94	0.33	0.88	0.77	0.9	0.96	0.9

Click cells to compare fundamentals

Jazz Pharmaceuticals Account Relationship Matchups

Jazz Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	57.6M	56.5M	59.7M	62.5M	72.1M	51.5M
Total Assets	5.5B	6.5B	12.3B	10.8B	11.4B	12.0B
Short Long Term Debt Total	1.8B	2.2B	6.1B	5.8B	5.8B	6.1B
Other Current Liab	278.8M	338.3M	650.5M	787.3M	739.4M	776.4M
Total Current Liabilities	364.5M	653.7M	809.3M	933.2M	1.5B	1.6B
Total Stockholder Equity	3.1B	3.7B	4.0B	3.1B	3.7B	3.9B
Other Liab	337.7M	233.9M	1.4B	1.0B	1.2B	1.3B
Property Plant And Equipment Net	270.9M	257.1M	343.4M	301.4M	235.0M	119.6M
Net Debt	1.1B	1.2B	5.5B	4.9B	4.3B	4.5B
Retained Earnings	1.1B	1.2B	830.2M	733.6M	878.7M	922.6M
Accounts Payable	47.5M	26.9M	100.3M	90.8M	102.8M	107.9M
Cash	637.3M	1.1B	591.4M	881.5M	1.5B	1.6B
Non Current Assets Total	3.9B	3.7B	9.7B	8.2B	8.0B	8.4B
Non Currrent Assets Other	47.9M	25.7M	40.8M	58.9M	69.2M	72.7M
Other Assets	272.2M	415.0M	363.9M	435.1M	171.5M	136.8M
Long Term Debt	1.6B	1.8B	6.0B	5.7B	5.1B	5.4B
Cash And Short Term Investments	1.1B	2.1B	591.4M	881.5M	1.6B	1.7B
Net Receivables	356.0M	396.5M	563.4M	651.5M	705.8M	741.1M
Good Will	920.0M	958.3M	1.8B	1.7B	1.8B	1.8B
Short Term Investments	515M	440M	1.1B	30M	120M	147.5M
Liabilities And Stockholders Equity	5.5B	6.5B	12.3B	10.8B	11.4B	12.0B
Non Current Liabilities Total	2.1B	2.2B	7.5B	6.8B	6.1B	6.4B
Inventory	78.6M	95.4M	1.1B	714.1M	597.0M	626.9M
Other Current Assets	78.9M	214.9M	383.8M	359.1M	334.8M	351.5M
Other Stockholder Equity	2.3B	2.6B	3.5B	3.5B	3.7B	3.9B
Total Liab	2.4B	2.9B	8.3B	7.7B	7.7B	8.0B
Property Plant And Equipment Gross	270.9M	257.1M	343.4M	301.4M	368.3M	386.8M
Total Current Assets	1.6B	2.8B	2.6B	2.6B	3.3B	3.4B
Accumulated Other Comprehensive Income	(223.4M)	(134.4M)	(400.4M)	(1.1B)	(842.1M)	(800.0M)
Intangible Assets	2.4B	2.2B	7.2B	5.8B	5.4B	5.7B
Property Plant Equipment	270.9M	127.9M	343.4M	301.4M	346.6M	363.9M
Current Deferred Revenue	4.7M	2.5M	2.1M	463K	35.1M	36.8M
Net Tangible Assets	(250.0M)	648.7M	(5.0B)	(4.3B)	(3.9B)	(3.7B)
Capital Surpluse	2.3B	2.6B	3.5B	3.5B	4.0B	2.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jazz Ebitda vs Cost Of Revenue Analysis

Ebitda vs Cost Of Revenue

Ebitda vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Ebitda

Cost Of Revenue

Jazz Pharmaceuticals fundamental ratios Correlations

Jazz Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jazz Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Jazz Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Long Term Debt
Total Liab	+ 1.0	Long Term Debt
Total Liab	+ 1.0	Non Current Liabilities Total
Non Current Assets Total	+ 0.99	Total Assets

Inventory	- 0.18	Short Term Investments
Short Term Investments	- 0.09	Other Liab
Non Current Liabilities Total	- 0.08	Short Term Investments
Short Term Investments	- 0.08	Net Debt
Short Term Investments	- 0.07	Long Term Debt
Short Term Investments	- 0.06	Accounts Payable